SUMOYLATION INHIBITOR TAK-981
Advanced or Metastatic Solid Tumors
TakedaSmall moleculePhase 1/2Dormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 73/ 100
Competitive context
62 Active assets in the Advanced or Metastatic Solid Tumors cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Pembrolizumab Hanmi Pharmaceutical Company Limited | Phase 1/2 | B |
Epirubicin Hanmi Pharmaceutical Company Limited | Phase 1/2 | B |
Cyclophosphamide Beijing Biotech | Phase 1/2 | B |
Eloxatin ASLAN Pharmaceuticals | Phase 1/2 | CCC |
CIS-DIAMMINEDICHLOROPLATINUM II Merck Sharp & Dohme LLC | Phase 1/2 | CCC |
View all 50 →
Same molecule, other indications
SUMOYLATION INHIBITOR TAK-981 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →